MedWatch

Genmab: Darzalex has been removed from trial with PD-1 inhibitors

According to Genmab, the biotech company's partner Janssen does not intend to begin a new study in Japan with the company's golden egg Darzalex and an experimental PD-1 inhibitor, as was otherwise reported by the website clinicaltrials.gov.

Foto: Tuala Hjarnø/Genmab

On Tuesday, MedWatch reported that the database clinicaltrials.gov recently registered a new study in Japan with the Genmab drug Darzalex and an experimental PD-1 inhibitor from the biotech company's US-based partner Janssen.

The study was registered in the database on June 6 - that is a week and a half after Darzalex failed in combination with a PD-L1 inhibitor from Roche, and Janssen, as a precaution, ended another study with Darzalex and the company's own experimental PD-1 inhibitor.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Headhunter: Afgående Leo-boss var et flop

Det var et fejlskud at ansætte Catherine Mazzacco som adm. direktør for Leo Pharma, vurderer headhunter, der ser afgangen som et naturligt skridt forud for børsnoteringen af Leo Pharma. Til at styre den proces i mål vil bestyrelsen efter alt at dømme skulle til udlandet for at finde den rette profil, lyder det videre.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier